Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ferula communis extract + ferutinin is a natural phytoestrogen-based botanical supplement derived from the non-toxic chemotype of *Ferula communis L.* (giant fennel). The extract is standardized to contain 20% ferutinin, a sesquiterpene ester that acts as a potent agonist of estrogen receptors (ERα and ERβ). Developed by researchers at the Magna Graecia University of Catanzaro (IRC-FSH), this nutraceutical is primarily investigated for the relief of postmenopausal symptoms and dysfunctions, including hot flashes, sexual behavior, and metabolic parameters like BMI. Clinical research published in 2024 demonstrated its efficacy in improving quality of life and reducing oxidative stress in postmenopausal women over a 90-day treatment period. Beyond menopausal relief, it has shown potential for the prevention of osteoporosis and as an antineoplastic agent due to its antiproliferative properties.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ferula communis extract + ferutinin.